Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
C4 Therapeutics, Inc. (CCCC) had Normalized Pre-Tax Income of $-26.32M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$7.24M |
|
$-26.32M |
|
-- |
|
$7.24M |
|
$36.40M |
|
$-29.16M |
|
$2.84M |
|
$-26.32M |
|
|
Normalized Pre-Tax Income |
$-26.32M |
$-26.32M |
|
$-26.32M |
|
$-26.32M |
|
$-26.32M |
|
$-29.16M |
|
$-29.49M |
|
70.83M |
|
70.83M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$232.53M |
|
$5.48M |
|
$86.99M |
|
$319.52M |
|
$40.82M |
|
-- |
|
$83.56M |
|
$124.38M |
|
$195.14M |
|
$195.14M |
|
$195.14M |
|
70.99M |
|
| Cash Flow Statement Financials | |
$-33.28M |
|
$29.12M |
|
$-0.05M |
|
$58.94M |
|
$54.74M |
|
$-4.21M |
|
$5.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-402.93% |
|
-402.93% |
|
-- |
|
-363.66% |
|
-363.66% |
|
$-33.28M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
0.90 |
|
99.82 |
|
-13.49% |
|
-13.49% |
|
-8.24% |
|
-13.49% |
|
$2.75 |
|
$-0.47 |
|
$-0.47 |
|